Torno Capital’s Vaxcyte PCVX Stock Holding History

Torno Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-25,000	Closed	-$2.05M	–	154
2024 Q4	$2.05M	Sell	25,000 -32,000	-56%	-$3.18M	0.18%	46
2024 Q3	$6.51M	Buy	+57,000	New	+$5.14M	0.99%	23

Other funds holding PCVX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Torno Capital's PCVX Position: Q1 2025 in Review

Torno Capital sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 7,000 shares — an estimated $573K sold.

Torno Capital first reported a position in PCVX in Q3 2024 and held it in 2 quarters. The position peaked at $1.03M in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

Torno Capital reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
Torno Capital sold 7,000 Vaxcyte shares in Q1 2025, an estimated $573K.
Torno Capital first reported a position in Vaxcyte in Q3 2024 and held it in 2 quarters.
Torno Capital's Vaxcyte position peaked at $1.03M in Q3 2024.
315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Torno Capital's 13F filing for Q1 2025, filed 14 May 2025.